Optimizing Weight Loss: Differentiating GLP-1 Therapies in Personalized Obesity Management

Meeting Objectives:

• • Describe obesity as a chronic disease, including its increasing prevalence, and review the current pharmacologic treatment landscape, highlighting FDA-approved indications and therapeutic roles of available weight loss medications. 
  • Evaluate obesity as a chronic disease, including its increasing prevalence, and review the current pharmacologic treatment landscape, highlighting FDA-approved indications and therapeutic roles of available weight loss medications. 
  • Apply clinical trial evidence to individualized treatment selection for patients with obesity through patient case-based discussions, incorporating comorbidities, patient preferences, and real-world access considerations.